Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CarraSorb FDG (Freeze-Dried Gel) is a sterile, preservative-free wound dressing containing acemannan, a polydispersed acetylated mannan extracted from *Aloe vera* gel. Developed by Carrington Laboratories, it received FDA 510(k) clearance in 1996 as a medical device for the management of wounds and burns. The product is a freeze-dried hydrogel that rehydrates upon contact with wound exudate to form a moldable gel, maintaining a moist healing environment. Beyond its physical properties, acemannan exhibits biological activity by stimulating macrophages and modulating the release of cytokines such as tumor necrosis factor (TNF) and interleukins, thereby enhancing the natural wound-healing process and natural killer (NK) cell activity.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on CarraSorb FDG.